clinical trial · NCT01961921
The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
TTR-mediated AmyloidosisALN-TTR02 (patisiran) administered by intravenous (IV) infusion
brief summary
The purpose of this study is to evaluate the safety and tolerability of long-term dosing with ALN-TTR02 (patisiran) in patients with transthyretin (TTR) mediated amyloidosis (ATTR).
started
Oct 1, 2013
primary completion
Jul 1, 2016
completion
Aug 1, 2016
last updated
Apr 19, 2024
official title
A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol